CHARLES M BALCH to Immunotherapy
This is a "connection" page, showing publications CHARLES M BALCH has written about Immunotherapy.
Connection Strength
0.440
-
Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready? Ann Surg Oncol. 2018 Jul; 25(7):1803-1806.
Score: 0.248
-
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res. 1998 Mar; 4(3):619-27.
Score: 0.061
-
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014 Oct; 40(9):1056-64.
Score: 0.048
-
Donald L. Morton, MD???a living legend in surgical oncology. J Surg Oncol. 2011 Sep; 104(4):338-40.
Score: 0.039
-
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo. 1991 Nov-Dec; 5(6):647-53.
Score: 0.010
-
A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO). Am Surg. 1986 Mar; 52(3):148-51.
Score: 0.007
-
Current status and future prospects for adjuvant therapy of melanoma. Aust N Z J Surg. 1984 Aug; 54(4):303-15.
Score: 0.006
-
Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery. 1984 Apr; 95(4):454-9.
Score: 0.006
-
The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments. Ann Surg. 1983 Aug; 198(2):164-7.
Score: 0.006
-
A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer. 1982 Mar 15; 49(6):1079-84.
Score: 0.005
-
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunol Immunother. 1991; 33(4):238-46.
Score: 0.002
-
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center. Cancer Treat Rev. 1989 Jun; 16 Suppl A:39-48.
Score: 0.002